Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma

BMC Cancer

Table 2 Results and characteristics of patients with cholangiocellular carcinoma and benign liver tumors

Patient	Liver disease/	Non-tumor tissue					Tumor tissue
	Primary cancer	Fibrosis	Methylight		MSP	IRS	Methylight		MSP	IRS
		score	Result	PMR			Result	PMR
Cholangiocellular carcinoma (CCC)
CCC1	bile duct	0	neg	0.01	pos	0	neg	0.01	neg	6
CCC2	bile duct	2	neg	0.01	neg	0	neg	0.04	neg	0
CCC3	bile duct	0	neg	0.01	neg	0	neg	0.01	pos	6
CCC4	bile duct	0	neg	0.01	neg	0	neg	0.8	pos	0
CCC5	gall bladder	0	neg	0.01	pos	0	pos	25.86	pos	2
CCC6	bile duct	0	neg	0.01	pos	2	neg	0.01	pos	2
CCC7	bile duct	2	neg	0.07	neg	0	neg	0.1	neg	5
CCC8	gall bladder	0	neg	0.01	neg	0	neg	3.28	neg	0
CCC9	bile duct	6	neg	0.01	neg	nd	neg	0.01	neg	nd
CCC10	bile duct	4	neg	0.49	neg	nd	neg	0.27	neg	nd
CCC11	gall bladder	1	neg	0.4	nd	nd	neg	0.01	nd	nd
Benign liver tumors (B)
B1	FNH	0	neg	0.34	neg	0	neg	0.05	neg	2
B2	FNH	0	neg	0.05	neg	0	neg	0.25	neg	5
B3	hepatic adenoma	0	neg	0.01	nd	0	neg	0.01	nd	2
B4	FNH	0	neg	0.62	neg	2	neg	0.07	neg	0
B5	FNH	0	neg	0.1	nd	nd	neg	0.04	nd	nd
B6	FNH	0	neg	0.07	nd	nd	neg	1.36	nd	nd
B7	FNH	0	neg	0.03	nd	nd	neg	0.26	nd	nd

PMR, percentage of methylated reference (%); MSP, methylation specific PCR, IRS = Immunoreactivity score; nd, not done; CCC, cholangiocellular carcinoma; FNH, focal nodular hyperplasia;

ISSN: 1471-2407